These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs. Borghardt JM; Weber B; Staab A; Kloft C AAPS J; 2015 Jul; 17(4):853-70. PubMed ID: 25845315 [TBL] [Abstract][Full Text] [Related]
64. Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery. Hu X; Yang FF; Liao YH Curr Pharm Des; 2016; 22(17):2532-48. PubMed ID: 26818873 [TBL] [Abstract][Full Text] [Related]
65. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Nahar K; Gupta N; Gauvin R; Absar S; Patel B; Gupta V; Khademhosseini A; Ahsan F Eur J Pharm Sci; 2013 Aug; 49(5):805-18. PubMed ID: 23797056 [TBL] [Abstract][Full Text] [Related]
66. Electrohydrodynamic methods for the development of pulmonary drug delivery systems. Nikolaou M; Krasia-Christoforou T Eur J Pharm Sci; 2018 Feb; 113():29-40. PubMed ID: 28865687 [TBL] [Abstract][Full Text] [Related]
68. Inhalation delivery of complex drugs-the next steps. de Kruijf W; Ehrhardt C Curr Opin Pharmacol; 2017 Oct; 36():52-57. PubMed ID: 28846876 [TBL] [Abstract][Full Text] [Related]
69. Drug delivery to the Lungs 21. Mitchell JP; Nichols SC Ther Deliv; 2011 Mar; 2(3):301-5. PubMed ID: 22834000 [TBL] [Abstract][Full Text] [Related]
70. Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics. Guillon A; Sécher T; Dailey LA; Vecellio L; de Monte M; Si-Tahar M; Diot P; Page CP; Heuzé-Vourc'h N Int J Pharm; 2018 Jan; 536(1):116-126. PubMed ID: 29180257 [TBL] [Abstract][Full Text] [Related]
73. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Tolman JA; Williams RO Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248 [TBL] [Abstract][Full Text] [Related]
74. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report. Evans C; Cipolla D; Chesworth T; Agurell E; Ahrens R; Conner D; Dissanayake S; Dolovich M; Doub W; Fuglsang A; García Arieta A; Golden M; Hermann R; Hochhaus G; Holmes S; Lafferty P; Lyapustina S; Nair P; O'Connor D; Parkins D; Peterson I; Reisner C; Sandell D; Singh GJ; Weda M; Watson P J Aerosol Med Pulm Drug Deliv; 2012 Jun; 25(3):117-39. PubMed ID: 22413806 [TBL] [Abstract][Full Text] [Related]
75. Establishing bioequivalence for inhaled drugs; weighing the evidence. Daley-Yates PT; Parkins DA Expert Opin Drug Deliv; 2011 Oct; 8(10):1297-308. PubMed ID: 21699442 [TBL] [Abstract][Full Text] [Related]
76. Inhaled Formulation Design for the Treatment of Lung Infections. Garcia-Contreras L; Yadav KS Curr Pharm Des; 2015; 21(27):3875-901. PubMed ID: 26290199 [TBL] [Abstract][Full Text] [Related]
77. Recent advances in the fundamental understanding of adhesive mixtures for inhalation. Grasmeijer F; Grasmeijer N; Hagedoorn P; Frijlink HW; Haaije de Boer A Curr Pharm Des; 2015; 21(40):5900-14. PubMed ID: 26446471 [TBL] [Abstract][Full Text] [Related]
78. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Bäckman P; Adelmann H; Petersson G; Jones CB Clin Pharmacol Ther; 2014 May; 95(5):509-20. PubMed ID: 24503626 [TBL] [Abstract][Full Text] [Related]
79. Factors Affecting Drug Exposure after Inhalation. Nováková A; Šíma M; Slanař O Prague Med Rep; 2022; 123(3):129-139. PubMed ID: 36107443 [TBL] [Abstract][Full Text] [Related]